Related references
Note: Only part of the references are listed.A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-tine therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
Stefan Faderl et al.
BLOOD (2008)
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
S Faderl et al.
BLOOD (2006)
Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'
AA Kassim et al.
BONE MARROW TRANSPLANTATION (2005)
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age
EP Alyea et al.
BLOOD (2005)
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias
S Faderl et al.
BLOOD (2005)
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia
H Kantarjian et al.
BLOOD (2003)
Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies
S Mineishi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Allogeneic hematopoietic stem cell transplantation - Yesterday, today, and tomorrow
R Storb
EXPERIMENTAL HEMATOLOGY (2003)
In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors
N Kröger et al.
BONE MARROW TRANSPLANTATION (2002)
Share Paper
